tag EpiPen

Mylan to pay $465 million over EpiPen Medicaid rebate dispute

EghtesadOnline: Mylan NV on Friday said it will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment, which has come under intense scrutiny after a series of drastic price increases.
|
Publish Date:09/October/2016 | 10:05

U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes

EghtesadOnline: U.S. lawmakers on Wednesday blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.
|
Publish Date:22/September/2016 | 11:41

Teva says aims to launch EpiPen -like device by 2018 in U.S.

EghtesadOnline: Teva Pharmaceutical Industries Ltd said Friday it aims to win U.S. approval by late 2017 or early 2018 for its version of Mylan NV's EpiPen device for treating severe allergic reactions, a move that would challenge the branded product's overwhelming market dominance.
|
Publish Date:10/September/2016 | 07:12

Senate investigations panel to probe Mylan's EpiPen pricing

EghtesadOnline: The U.S. Senate's permanent subcommittee on investigations will probe Mylan Pharmaceuticals' pricing of the allergy auto-injector EpiPen , according to a press release issued on Wednesday.
|
Publish Date:08/September/2016 | 08:00

Senators press Mylan on 'exorbitantly expensive' EpiPen

EghtesadOnline: Democrat Elizabeth Warren and 19 other U.S. senators voiced concern to the chief executive of Mylan NV about the high cost of its EpiPen on Tuesday, calling the device used in the case of life-threatening allergies "exorbitantly expensive."
|
Publish Date:31/August/2016 | 07:44

Mylan to launch generic EpiPen at half the price of original

EghtesadOnline: Mylan NV said it would launch the first generic version of its allergy auto-injector EpiPen for $300, half the price of the branded product, the drugmaker's second step in less than a week to counter the backlash over the product's steep price.
|
Publish Date:30/August/2016 | 07:21